Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Proof-of-concept phase I data for mitapivat, an oral, small molecule inhibitor of pyruvate kinase R, shows early evidence of efficacy and safety in patients with stable sickle cell disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 194 KB
Released: December 16, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

On-demand webcast from a satellite symposia at the 2021 Hematology meeting on diagnosis and management of aTTP, from Clinical Care Options (CCO)

Ara Metjian, MD
Program Director
Paul Coppo, MD, PhD Marshall Mazepa, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: January 26, 2022 Expired: January 25, 2023

Download this short slideset from Clinical Care Options (CCO) on the management of newly diagnosed and relapsed light-chain (AL) amyloidosis

Ankit Kansagra, MD Shaji K. Kumar, MD Vaishali Sanchorawala, MD Released: January 19, 2022

Downloadable PDF summary transcript of expert answers to questions on hemophilia A management, from Clinical Care Options (CCO)

Miguel A. Escobar, MD Mark Reding, MD Guy A. Young, MD Released: January 18, 2022

Downloadable summary slideset from a live ASH 2021 satellite symposium on optimizing outcomes in hemophilia A with factor and nonfactor therapy from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Mark Reding, MD Guy A. Young, MD
Released: December 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings